Gamma Medica

Gamma Medica

Gamma Medica is a U.S.-based company that provides molecular breast imaging (MBI) technology developed by the Mayo Clinic and commercialized by Gamma Medica, MBI is a type of functional imaging that relies on the biochemical and physiological features of tumors to detect breast cancer, rather than the visual features revealed via mammography. MBI is a highly accurate, easy to use technology that produces images that can be interpreted quickly.

In conjunction with Gamma Medica, WellNovation recently secured Saudi Food & Drug Authority approval for MBI. Additionally, we are working with a number of local public and private healthcare providers to determine the optimal way to incorporate molecular breast imaging into the current screening protocols and anticipate that a pilot project will be in place by mid-2016.

Molecular breast imaging uses a specialized cadmium zinc telluride (CZT)-based gamma camera in a dual-detector configuration to image the functional uptake of a radiotracer that accumulates preferentially in cancerous cells, clearly distinguishing between benign and malignant tissue. MBI is highly sensitive and can detect tumors as small as 5 millimeters irrespective of breast density, produces easy to interpret images, and generates fewer recalls than other secondary screening modalities, all at a fraction of the cost of breast MRI.

Molecular breast imaging is currently being used by the Mayo Clinic and other leading cancer centers in the U.S. as the preferred supplemental screening method for women with dense breasts. Adding MBI to mammography increases the cancer yield from 3.2 per 1000 with mammography alone to 12.0 per 1000 without an unacceptably high increase in false positive findings. Furthermore, a number of American cancer centers have begun testing MBI’s feasibility and performance as a primary screening modality.

Dr. Deborah Rhodes TED Talk: A Test That Finds 3x More Breast Tumors, and Why It’s Not Available to You

Dedicated Dual-Head Gamma Imaging for Breast Cancer Screening in Women with Mammographically Dense Breasts

Molecular Breast Imaging May Increase Cancer Detection for Women with Dense Breasts